Long-Term Followup of a Multicenter Cohort of 101 Patients with Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss)

Arthritis Care and Research

Volumn 68, Issue 3, 2016, Pages 374-387

  Durel, Cécile Audrey ^a   Berthiller, Julien ^b   Caboni, Silvia ^c   Jayne, David ^d   Ninet, Jacques ^a   Hot, Arnaud ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UNIVERSITÉ DE LYON   (France)

^c Specialista Ambulatoriale Allergologia e Immunologia Clinica   (Italy)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; NEUTROPHIL CYTOPLASMIC ANTIBODY; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGE; AGED; ARTICLE; CARDIOMYOPATHY; CHRONIC KIDNEY DISEASE; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; CORRELATIONAL STUDY; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; EAR NOSE THROAT DISEASE; ETHNICITY; FEMALE; FIVE FACTOR SCORE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ITALIAN (CITIZEN); KIDNEY DISEASE; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONONEUROPATHY; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PROGNOSIS; RECURRENCE FREE SURVIVAL; REMISSION; RETROSPECTIVE STUDY; RISK REDUCTION; SCORING SYSTEM; SURVIVAL RATE; ADOLESCENT; BLOOD; CHURG-STRAUSS SYNDROME; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; EUROPE; MULTICENTER STUDY; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; BIOMARKERS; CHURG-STRAUSS SYNDROME; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84959319475     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22686     Document Type: Article

References (47)

1. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al., Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92.
2. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al., 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65: 1-11.
3. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P., Churg-Strauss syndrome: clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78: 26-37.
4. Sinico RA, Di Toma L, Maggiore U, Bottero P, Radice A, Tosoni C, et al., Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005; 52: 2926-35.
5. Sable-Fourtassou R, Cohen P, Mahr A, Pagnoux C, Mouthon L, Jayne D, et al., Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005; 143: 632-8.
6. Keogh KA, Specks U., Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003; 115: 284-90.
7. Della Rossa A, Baldini C, Tavoni A, Tognetti A, Neglia D, Sambuceti G, et al., Churg-Strauss syndrome: clinical and serological features of 19 patients from a single Italian centre. Rheumatology (Oxford) 2002; 41: 1286-94.
8. Solans R, Bosch JA, Perez-Bocanegra C, Selva A, Huguet P, Alijotas J, et al., Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology (Oxford) 2001; 40: 763-71.
9. Samson M, Puechal X, Devilliers H, Ribi C, Cohen P, Stern M, et al., Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. J Autoimmun 2013; 43: 60-9.
10. Bremer JP, Csernok E, Holle J, Gross WL, Moosig F., Getting rid of MPO-ANCA: a matter of disease subtype. Rheumatology (Oxford) 2013; 52: 752-4.
11. Watts RA, Scott DG., ANCA vasculitis: to lump or split? Why we should study MPA and GPA separately. Rheumatology (Oxford) 2012; 51: 2115-7.
12. Baldini C, della Rossa A, Grossi S, Catarsi E, Talarico R, d'Ascanio A, et al., Churg-Strauss syndrome: outcome and long-term follow-up of 38 patients from a single Italian centre. Reumatismo 2009; 61: 118-24. In Italian.
13. Pagnoux C, Guillevin L., Churg-Strauss syndrome: evidence for disease subtypes? Curr Opin Rheumatol 2010; 22: 21-8.
14. Roufosse F, Weller PF., Practical approach to the patient with hypereosinophilia. J Allergy Clin Immunol 2010; 126: 39-44.
15. Conron M, Beynon HL., Churg-Strauss syndrome. Thorax 2000; 55: 870-7.
16. Mukhtyar C, Flossmann O, Hellmich B, Bacon P, Cid M, Cohen-Tervaert JW, et al., Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008; 67: 1004-10.
17. Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al., Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009; 68: 1827-32.
18. Pagnoux C, Guilpain P, Guillevin L., Churg-Strauss syndrome. Curr Opin Rheumatol 2007; 19: 25-32.
19. Dunogue B, Pagnoux C, Guillevin L., Churg-Strauss syndrome: clinical symptoms, complementary investigations, prognosis and outcome, and treatment. Semin Respir Crit Care Med 2011; 32: 298-309.
20. Cohen P, Pagnoux C, Mahr A, Arene JP, Mouthon L, le Guern V, et al., Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 2007; 57: 686-93.
21. Ribi C, Cohen P, Pagnoux C, Mahr A, Arene JP, Lauque D, et al., Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 2008; 58: 586-94.
22. Comarmond C, Pagnoux C, Khellaf M, Cordier JF, Hamidou M, Viallard JF, et al., Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 2013; 65: 270-81.
23. Gayraud M, Guillevin L, le Toumelin P, Cohen P, Lhote F, Casassus P, et al., Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001; 44: 666-75.
24. Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al., The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33: 1094-100.
25. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al., Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM Mon J Assoc Physicians 1994; 87: 671-8.
26. Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, et al., Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome: a prospective study in 342 patients. Medicine (Baltimore) 1996; 75: 17-28.
27. Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, le Toumelin P, et al., The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011; 90: 19-27.
28. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al., EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68: 310-7.
29. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, et al., Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997; 40: 371-80.
30. Seo P, Jayne D, Luqmani R, Merkel PA., Assessment of damage in vasculitis: expert ratings of damage. Rheumatology (Oxford) 2009; 48: 823-7.
31. Swanney MP, Ruppel G, Enright PL, Pedersen OF, Crapo RO, Miller MR, et al., Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax 2008; 63: 1046-51.
32. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis Off J Natl Kidney Found 2002; 39 Suppl 1: S1-266.
33. Moosig F, Bremer JP, Hellmich B, Holle JU, Holl-Ulrich K, Laudien M, et al., A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis 2013; 72: 1011-7.
34. Hauser T, Mahr A, Metzler C, Coste J, Sommerstein R, Gross WL, et al., The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study. Thorax 2008; 63: 677-82.
35. Noth I, Strek ME, Leff AR., Churg-Strauss syndrome. Lancet 2003; 361: 587-94.
36. Mouthon L, Dunogue B, Guillevin L., Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg-Strauss syndrome). J Autoimmun 2014; 48: 99-103.
37. Neumann T, Manger B, Schmid M, Kroegel C, Hansch A, Kaiser WA, et al., Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) 2009; 88: 236-43.
38. Vaglio A, Buzio C, Zwerina J., Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of the art. Allergy 2013; 68: 261-73.
39. Jeong YJ, Kim KI, Seo IJ, Lee CH, Lee KN, Kim KN, et al., Eosinophilic lung diseases: a clinical, radiologic, and pathologic overview. Radiogr Rev Publ Radiol Soc N Am Inc 2007; 27: 617-37.
40. Valent P, Klion AD, Horny HP, Roufosse F, Gotlib J, Weller PF, et al., Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 2012; 130: 607-12.e9.
41. Mahr A, Moosig F, Neumann T, Szczeklik W, Taille C, Vaglio A, et al., Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): evolutions in classification, etiopathogenesis, assessment and management. Curr Opin Rheumatol 2014; 26: 16-23.
42. Walsh M, Merkel PA, Mahr A, Jayne D., Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res (Hoboken) 2010; 62: 1166-73.
43. Mahr A, Katsahian S, Varet H, Guillevin L, Hagen EC, Hoglund P, et al., Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. Ann Rheum Dis 2013; 72: 1003-10.
44. Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, et al., Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 2012; 64: 3452-62.
45. Bligny D, Mahr A, le Toumelin P, Mouthon L, Guillevin L., Predicting mortality in systemic Wegener's granulomatosis: a survival analysis based on 93 patients. Arthritis Rheum 2004; 51: 83-91.
46. Seo P, Stone JH., Small-vessel and medium-vessel vasculitis. Arthritis Rheum 2007; 57: 1552-9.
47. Merkel PA., Defining disease activity and damage in patients with small-vessel vasculitis. Cleve Clin J Med 2012; 79 Suppl 3: S11-5.